Navigation Links
ALS Therapy Development Institute and Oxford BioMedica Begin Second Phase of Collaboration to Develop Gene Therapies for Amyotrophic Lateral Sclerosis
Date:1/27/2010

zens of potential therapeutics each year.  Built by and for patients, the Institute is the world's only non-profit biotechnology company with more than 30 professional scientists. In addition, the Cambridge, Massachusetts based research Institute collaborates with leaders in both academia and industry.  For more information, please visit us online at www.als.net.

About Oxford BioMedica

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient gene delivery system (LentiVector®), which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline. Partners include sanofi-aventis, Sigma-Aldrich and Pfizer. Technology licensees include Biogen-Idec, GlaxoSmithKline, Merck & Co and Pfizer. Further information is available at www.oxfordbiomedica.co.uk.

About MDA

MDA (www.mda.org) is the world's largest nonprofit provider of ALS
'/>"/>

SOURCE ALS Therapy Development Foundation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
2. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
3. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
4. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
5. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
6. Elekta Contract Provides Sisters of Mercy Health System Access to Leading Radiation Therapy Solutions
7. Varian Medical Systems Exhibits Latest Technologies and Products Designed to Improve Speed and Precision of Radiotherapy at ESTRO 2007
8. Elekta Displays Complete Volumetric Intensity Modulated Arc Therapy Solutions at ESTRO
9. Stem Cell Therapy to Skyrocket by 2017
10. Team demos safety of RNA therapy
11. First European IGRT School Takes Place for Radiotherapy Practitioners in UK
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... OAKS, Calif., July 10, 2014   Ceres, Inc ... and seed company, announced today financial results for the ... update on its business. Ceres reported that ... in product performance this growing season in Brazil, which ... affected the company,s sorghum evaluation areas for part of ...
(Date:7/10/2014)... 2014 Using microscopic polymer light resonators that ... at MIT,s Quantum Photonics Laboratory have developed new ... parts-per-billion range. Optical sensors are ideal for detecting ... ratio, compact, lightweight nature, and immunity to electromagnetic ... been developed before, the MIT team conceived an ...
(Date:7/10/2014)... fractional quantum Hall effect in bilayer graphene and shown ... by an electric field. , The fractional quantum ... thin sheets are exposed to large magnetic fields, is ... individual electrons behave as a single system. However, while ... many details of this collective behavior remain not well ...
(Date:7/10/2014)... out for crude 3-D glasses, polarized glasses, and ... basic devices, used to trick the brain into ... rendered obsolete with the introduction of new holography ... TAU doctoral students Yuval Yifat, Michal Eitan, and ... on nanoantennas that could be used for security ...
Breaking Biology Technology:Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9Swell new sensors 2Columbia researchers observe tunable quantum behavior in bilayer graphene 2Columbia researchers observe tunable quantum behavior in bilayer graphene 3Projecting a 3-dimensional future 2Projecting a 3-dimensional future 3
... , , , BALTIMORE, ... (OTC Bulletin Board: CSBR), a company engaged in the development ... the value of oncology drugs, has established yet another agreement ... novel oncology therapeutic in Champions, Biomerk Tumorgraft(TM) platform. , ...
... , , ROCKVILLE, Md., ... today favorable results from a Phase II human clinical trial of ... vaccine was well tolerated and induced robust immune responses against all ... support the planned study in elderly adults scheduled for the fourth ...
... COPENHAGEN and OSLO, September 1 Affitech ... announced that it,has appointed two experienced biotech executives ... CEO of Celldex Therapeutics Inc., has today,assumed overall ... Dr Alexander Duncan, previously SVP Biopharmaceuticals for Astra,Zeneca ...
Cached Biology Technology:Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader 2Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader 3NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus-like Particle (VLP) Vaccine Candidate 2NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus-like Particle (VLP) Vaccine Candidate 3NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus-like Particle (VLP) Vaccine Candidate 4NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus-like Particle (VLP) Vaccine Candidate 5Affitech Appoints Dr Robert Burns as CEO and Dr Alexander Duncan as SVP Research & Development 2Affitech Appoints Dr Robert Burns as CEO and Dr Alexander Duncan as SVP Research & Development 3
(Date:7/11/2014)... Society for Bone and Mineral Research awarded Michael F. ... (BUSM), with the 2014 Louis V. Avioli Award. Holick, ... is internationally known for revolutionizing the understanding of vitamin ... The award honors a member of the American Society ... to bone and mineral basic research. It is named ...
(Date:7/11/2014)... . X-ray ... of X-rays through a specimen instead of attenuation resulting ... often of much higher quality than those based on ... Pfeiffer are particularly interested in developing new approaches for ... imaging. One main goal is to make this method ...
(Date:7/11/2014)... the National Institute of Standards and Technology (NIST) ... more effectively, they often prove that necessity is ... case recently for M. Lorna De Leoz and ... specialization of glycomics. Glycomics is the study of ... are attached to proteins and lipids and influence ...
Breaking Biology News(10 mins):BUSM's Michael F. Holick receives American Society for Bone and Mineral Research award 2New simple setup for X-ray phase contrast 2
... a future when man and machine would become one. ... futuristic "vision" of bionics a reality. Prof. Yael ... has foundational research that may give sight to blind ... growth. Successful so far in animal models, this research ...
... Calif., March 19, 2010Under a changing climate, patterns ... how will forest diseases respond? A summary of ... available on the Internet at http://www.fs.fed.us/psw/topics/insect_disease/ . ... titled "Review of Literature on Climate Change and ...
... big jobs in our environment, to go dormant not only ... also play a key role in promoting biodiversity and ecosystem ... Proceedings of National Academy of Sciences , Michigan State ... a mathematical model and molecular tools to study how dormancy ...
Cached Biology News:Seeing a bionic eye on medicine's horizon 2How will tree diseases react to climate change? 2Dormant microbes promote diversity, serve environment 2
... standard fixed-angle microcentrifuge rotor at RCF ... tube filters consist of a membrane-containing ... They filter by centrifugation for bacteria ... removal of cells from media and ...
These Costar 96-well, flat-bottom polystyrene EIA plates are used for EIAs, ELISAs, and other protein binding assays. Supplied as box of 100 (20 packages; 5 plates per package)....
... System provides high-throughput, quantitative gene expression analysis ... patented priming strategy overcomes the biases that ... a few genes at a time. ... and more samples per run, removing bottlenecks ...
... provides a convenient method to probe conformational changes ... substrates. Thus, the kit may be used to ... as transport substrates for MDR1. Because UIC2 binding ... substrates, the MDR1 Shift Assay can be utilized ...
Biology Products: